Securities Code●4559

健康づくりは幸せづくり
Making Healthis making happiness

67th

Business Report
From April 1st, 2020 to March 31st, 2021

Contents
To Our Shareholders …………………………………………… P.1
Summary of Our Business Operations (Consolidated) ……… P.3
Status of Research and Development ………………………… P.5
Research and Development Pipeline ………………………… P.6
Status of Production and Distribution /Outlook for Fiscal Year 2021 ………………………………… P.7
Special Offers to Our Shareholders …………………………… P.8
Topics …………………………………………………………… P.9
Financial Statements (Consolidated) ………………………… P.11
Company Information ………………………………………… P.13
Share Information ……………………………………………… P.14
Shareholder MemoTo Our Shareholders

We, Zeria Pharmaceutical Co., Ltd. (“Zeria”)
would like to express our thanks for yourparticular support.
We are pleased to report the businessresults of fiscal year 2020 (67th business
operations) for the period from April 1st,
2020 to March 31st, 2021.

1

Chairman and CEO

President and COO

Sachiaki Ibe

Mitsuhiro IbeDuring the fiscal year under review, business activity in the Japanese economy was severely restricted by two declarations of a state of
emergency in response to the spread of infection of the novel coronavirus (COVID-19). The COVID-19 pandemic will continue to affect theeconomy going forward resulting in an ongoing sense of uncertainty.
In the pharmaceutical industry, the market environment for ethical pharmaceuticals has become even more severe due to further
strengthening of initiatives to curtail healthcare expenses, such as the promotion of the use of generic brand pharmaceuticals, as well as pricerevisions on a roughly annual basis. In addition to this, there has also been a heavy impact from people avoiding visiting medical facilities
because of the COVID-19 pandemic. The market environment for OTC drugs is just as severe as for ethical pharmaceuticals due to increasingly
fierce market competition, as well as factors such as measures to refrain from going outside and a significant fall in demand from foreign
visitors to Japan caused by steep decline in people entering the country from abroad.
Under such circumstances, the Zeria Group entered the first year of its 10th Mid-Term Management Plan (fiscal year 2020 to fiscal year 2022).
The Group has been accelerating global expansion during the fiscal year under review, which has steadily expanded overseas sales. We havebeen proactive in creating M&A and alliances and in April 2020, we made Kenso-Seiyaku Co., Ltd. into a subsidiary. Kenso-Seiyaku is engaged
in the manufacture and sale of liver hydrolysate, one of the core ingredients of the Hepalyse range, as well as OTC pharmaceuticals, healthfoods, and other products. Furthermore, in November 2020, our European subsidiary Tillotts Pharma AG succeeded to the rights to
manufacture and sell DIFICLIR, a treatment for Clostridium difficile infections, in Europe, the Middle East, Africa, and the Commonwealth of
Independent States from Astellas Pharma Europe Ltd.
However, our businesses in Japan are struggling due to the effects of the COVID-19 pandemic, particularly with regard to sales of the
Hepalyse range, our main brand in the Consumer Healthcare business.
As a result of these activities, net sales for the current fiscal year were 55,442 million yen, down 8.2% from the previous fiscal year. Regarding
profits, operating profit was 3,442 million yen, down 15.9% from the previous fiscal year, and ordinary profit was 3,175 million yen, down
18.2% from the previous fiscal year. On the other hand, a reversal of debt and gain on sale of investment securities were recorded as
extraordinary income, resulting in profit attributable to owners of parent of 3,119 million yen (up 6.6% from the previous fiscal year).
In the current fiscal year, the overseas sales to net sales ratio was 34.4%, compared with 31.0% in the previous fiscal year.

Net sales

Operating profit ( )/Ordinary profit ( )/Profit attributable to owners of parent ( )(Unit: ¥million)

80,00060,000(Unit: ¥million)

6,000

61,83160,42655,4424,000

3,737 3,295
3,454

4,094 3,879

Fiscal Year 2018

Fiscal Year 201940,000

2,925

3,442

3,175
3,119

2,000
20,000
0

0

Fiscal Year 2018

Fiscal Year 2019

Fiscal Year 2020

Fiscal Year 20202

Summary of Our Business Operations (Consolidated)

Ethical Pharmaceuticals Business
As for the main product, Asacol, a therapeutic agent for ulcerative
colitis, the domestic market saw an impact from competitive
products as well as generic brands and there were also effects
from price revisions in both October 2019 and April 2020.
However, the termination of a sales alliance with Kyowa Kirin Co.,
Ltd. at the end of March 2020 meant that from April 2020, it was
exclusively sold by Zeria. As a result, sales increased compared tothe previous fiscal year. Sales grew in overseas markets, due to acontribution from Asacol 1600mg and favorable trends incountries such as the UK and France. On the other hand, there
was a slight decrease in sales of Entocort, the inflammatory bowel
disease therapeutic agent (domestic sales name: Zentacort) due tothe impact of price revisions in some regions, such as France, anddelays to shipping times. As for Acofide, the therapeutic agent forfunctional dyspepsia, the termination of a sales partnership with
Astellas Pharma Inc. at the end of March 2021 meant that from
April 2021, it was exclusively sold by Zeria. However, sales
decreased during the fiscal year under review due to factors suchas inventory adjustments accompanying the termination of thesales partnership, people avoiding visiting medical facilities, and adecrease in endoscopic examinations. Additionally, in September
2020, we began sales of Ferinject solution for injection/infusion
500mg, a treatment for iron deficiency anemia and we areworking to realize swift market penetration.
As a result, net sales in the business amounted to 30,023 million
yen (down 5.5% from the previous fiscal year).

Net sales

30,023 million¥

down 5.5%
from the previous fiscal year

Net sales of major products
Consumer
Healthcare
Business

Asacol54.2%

Net sales(composition
ratio)

Entocort
AcofideOther

Asacol¥16.5 billion

Entocort¥4.8 billion

Acofide¥1.6 billion

Consolidated net sales
in Ethical Pharmaceuticals Business
35,00031,83030,00031,768(Unit: ¥million)

30,02325,00020,00015,0000
Fiscal Year 20183

Fiscal Year 2019 Fiscal Year 2020

Consumer Healthcare Business
As for the main brands, the Hepalyse range and the Chondroitin
range, we continued to develop sales promotion activities thatshowcase the characteristics of the products, but sales struggled
due to the impact of factors such as measures to refrain fromgoing outside due to the COVID-19 pandemic, a significant fall indemand from foreign visitors, and fierce competition with othercompanies’ products. However, amid the COVID-19 pandemic,
there was growth in the sales of certain hygienic products, such as
hand soaps and sanitizers, and we also recorded sales as the resultof the consolidation of Kenso-Seiyaku Co., Ltd. into a subsidiary.
Despite this, sales decreased overall. Additionally, during the fiscal
year under review we launched new products including Chondroamino Ca Tablets and Prevaline MyCare.

Net sales

25,261 million

down 11.4%¥

from the previous fiscal year

Net sales of major products
EthicalPharmaceuticals
Business

Hepalyse
range

45.6%

Chondroitin
range
WithOnerange

Net sales(composition
ratio)Other

As a result, net sales in the business amounted to 25,261 million
yen (down 11.4% from the previous fiscal year).
Hepalyse range¥7.5 billion

Chondroitin range¥6.0 billion

WithOne range¥1.6 billion

Consolidated net sales
in Consumer Healthcare Business

(Unit: ¥million)

35,00030,000

OTC drugs

29,841

28,50225,261

25,00020,00015,000
0

Hepalyse W series

Fiscal Year 2018 Fiscal Year 2019

Fiscal Year 2020®

4

Status of Research and Development

In the Research and Development division, Zeria is

In the area of Consumer Healthcare products, in November

promoting new drug research and development, centered2020, we obtained approval for the manufacturing andon the priority gastrointestinal field under a global

marketing of Belfemin, a treatment based on European

development structure in coordination with Tillotts

herbal medicines for ameliorating foot swelling caused by

Pharma AG.

mild venous insufficiency. We are continuing to pushahead with development based on European herbal

In September 2020, we launched Z-213, a treatment for

medicines, and have also launched new products oneiron deficiency anemia and an in-licensed drug from Vifor

after another, including Chondro-amino Ca Tablets and(International) AG of Switzerland, in Japan as FerinjectPrevaline MyCare.

solution for injection/infusion 500mg.
As a result of these activities, research and development
We are also conducting a global Phase III clinical trial for

expenses for the current fiscal year were 5,411 million yen

Z-100, which is targeting a cure for cervical cancer, in(down 14.7% from the previous fiscal year).

seven countries in the Asian region including Japan. All
patient enrollments planned to present have been
completed and we are continuing to carry out follow-up
studies on patients with a view to concluding the trial.
Regarding Zeria’s own original drug Z-338 (Acofide),
Phase III trials are being conducted for paediatricfunctional dyspepsia patients in Japan.
Phase III trials have commenced in Japan for ZG-801, atherapeutic agent for hyperkalemia in-licensed from Vifor( I n t e r n a t i o n a l ) A G o f S w i t z e r l a n d . We a re a l s oparticipating in Vifor (International) AG’s global clinical
trials aimed at expanding the indications of the drug. The
trials target chronic heart failure patients with a history of
hyperkalemia and have entered Phase III in Japan.
5Research and Development Pipeline

Status of Pipeline of New Drugs
I. Domestic
Stage
Phase III(As of May 11, 2021)
Development Code/
Generic Name

Development

Indications

Classification

Source

Z-100

Zeria

Cervical cancer

Immunomodulator

Original

Phase IIIZ-338/Acotiamide

Zeria

Paediatric functional
dyspepsia

Upper gastrointestinal
motility modulator

Original

Phase III

ZG-801/Patiromer Sorbitex Calcium

Zeria

Hyperkalemia

Potassium binder

In-licensed

Phase III

ZG-801/Patiromer Sorbitex Calcium

Zeria

Chronic heart failure
accompanying
Potassium binder
hyperkalemia(Asia Global Development)

In-licensed(participation in
global clinical trials)

Products developed and launched
Launch Date

Development Code/
Generic Name

September 1, 2020

Z-213/Ferric carboxymaltose(Sales name: Ferinject solution
for injection/infusion 500mg)

Development

Indications
Iron deficiency
anemiaZeria

Classification
Intravenous ironreplacement

Notes
In-licensed

II. Overseas
Stage

Development Code/
Generic Name

Development

Indications

Classification

SourceApproval(China)Z-206/Mesalazine

Co-development of Zeria
Ulcerative colitis
and Tillotts Pharma

pH-dependent controlled- Original
release formulation(Tillotts Pharma AG)

Phase III(Europe)

Z-338/Acotiamide

Zeria

Functional dyspepsia

Upper gastrointestinal
motility modulator

Original

Z-100

Zeria

Cervical cancer

Immunomodulator

Original

Phase III
(Asia Global Development)

Reference

Phase I Clinical Trials

Phase II Clinical Trials

Phase III Clinical Trials

After confirmation of the efficacy and safety byanimal studies, “drug candidates” are tested ona small group of healthy subjects. These trials
aim for determination of not only safety, but also
how long it takes for the body through anabsorption of the drug and the degree to which
the body excretes the drug.

After safety has been confirmed by Phase
I clinical trials, the efficacy and safety of
the “drug candidate,” as well as theappropriate method of use such as dosage
and administration method, are tested ona small number of patients against
placebo*.

By administering to a large number of patients, the efficacy,
safety and method of use of the “drug candidate” arestudied as a final stage. During this phase, the “drugcandidate” is tested against other drugs on the market orplacebo*. In many cases, stringent testing methods called
double-blind trials are performed.

* Placebo: A fake drug that does not contain the active ingredient, but which is indistinguishable from the “drug candidate” by outer appearance or taste, etc.

6

Status of Production and Distribution / Outlook for Fiscal Year 2021

● Status of Production and Distribution
In Zeria’s Production and Distribution division, we are advancing
process improvements, the introduction of energy-saving
equipment, and cost reductions based on the premise of securing
quality, while taking measures to prevent the spread of COVID-19
infections.
In departments related to Production, the COVID-19 pandemic
has made supplies of the raw materials needed to manufacture
pharmaceuticals unstable, particularly raw materials imported
from overseas. Within this environment, we are actively making
multiple purchases of raw materials and working to ensure wehave stocks of the materials required to continue supplying
pharmaceuticals. Additionally, at each of our plants, we areresponding to the risk of operational stoppages by moving
production forward to build up stocks of our products so that we
can maintain a stable supply structure. Also, in preparation for the
implementation of revisions to the ministerial ordinance on GMP(Good Manufacturing Practices – standards for manufacturingand quality controls relating to pharmaceuticals and quasi-drugs)
targeting quality assurance (enacted on August 1, 2021), we
have strengthened the education and training of plant employees
and enhanced GMP-related organizations. Furthermore, we havebegun reviewing the production facilities at four plants in Japan,
including two belonging to subsidiaries (Kenso-Seiyaku Co.,
Ltd.’s Tsukuba Plant and IONA INTERNATIONAL CORPORATION’s
Fukushima Plant). Going forward, we will work to further reduce
costs through initiatives such as consolidating production andpromoting inhouse manufacturing.
In departments related to Distribution, we moved the location of

the Tokyo Distribution Center and began joint delivery with KensoSeiyaku Co., Ltd. We will continue aiming to reduce distribution
costs as a Group by optimizing distribution systems and working
to make operations even more efficient.
In response to cases of large scale recalls by some genericpharmaceutical manufacturers and distributors that occurred in
the fiscal year under review due to manufacturing conditions thatdiverged from approval documents and violations of ministerial
ordinance on GMP, we carried out full inspections at each of
our plants. These inspections confirmed there are no such issues
within the Group. We will ensure that there continues to be noissues going forward by strengthening education and training
efforts at each plant, enhancing departments related to quality
control, and reinforcing our framework for oversight by therelevant departments at Headquarters.

● Outlook for Fiscal Year 2021
With no end to the COVID-19 pandemic in sight, in the EthicalPharmaceuticals Business, we expect sales to increase in overseas
markets due to factors such as a full-year contribution to sales
from DIFICLIR, for which we have received the manufacture andsales right in territories including Europe, and growth in sales of
Asacol 1600mg. In Japan, we expect to see growth in sales ofFerinject solution for injection/infusion 500mg, as well as Acofide
tablets, which has been sold exclusively by Zeria since April 2021.
Regarding the Consumer Healthcare business, we expect increases
in sales due to the introduction of multiple new products andthe strengthening of sales promotion activities that respond to
consumers’ needs and changes in consumer behavior.

There have been changes to some of the special offers to our shareholders options (effective March 31, 2021)

Option B

NewOld

Assortment of Chondro Support® (dietary supplement)
1 pack of 288 tablets
3 pouches of 90 tablets

2 bottles of Chondrobe® Concentrate, JUNKOU®
(health drink)

10 bottles of Hepalyse® W TANSAN

Option H (carbonated drink)
7

10 bottles of Hepalyse® W (soft drink)Special Offers to Our Shareholders

Zeria offers a hospitality program to its shareholders in recognition of their constant support.
Shareholders who own 1,000 or more of Zeria’s shares can choose from one of the seven options A to G.
Shareholders who own 100 or more but less than 1,000 of Zeria’s shares receive option H.
Zeria hopes its shareholders will try the gift products for better understanding of the Zeria Group’s
wide-ranging product structure.

OptionA

OptionE

Soft drinks, Designated quasi-drug,
Food for specified health uses

Three-product Quality
Moisturizer Set

Set of an assortment of aluminum
can drinks and Hepalyse® W

IONA Three-productBasic Skincare Set

OptionB

Dietary supplement

Assortment of Chondro Support®
1 pack of 288 tablets
3 pouches of 90 tablets

OptionC

Cosmetics, quasi-drug anddietary supplement

Set of ChondroMax®
and Aposty®

OptionD

OptionF

High-quality moisturizing skincare
based on chondroitin research

IONA R Two-productSpecial Care Set

OptionG

Health supplement

SEAALPA® 100
1 pack of 180 tablets

OptionH

Chondroitin-Content Intensive
Nighttime Essence

Carbonated drink
containing liver extract

2 bottles of
ZZ:CC® ADSORB ESSENCE

10 bottles of
Hepalyse® W TANSAN

Options D, E and F are available at the Zeria online store (https://www.zeriaonline.com/).
Option G is available through its official retailer – the Research Association for the Future Enhancement of Health Member’s Store(see the Kenso-Seiyaku Co., Ltd. website: http://www.kenso-seiyaku.co.jp).

8Topics

Commenced selling Ferinject® solution for injection/infusion 500mg, a treatment for iron deficiency anemia
On September 1, 2020, Zeria commenced selling Ferinject solution for injection/infusion 500mg (genericname: Ferric carboxymaltose; hereinafter “this treatment”), a treatment for iron deficiency anemia.
This treatment is a leading product of non-dextran intravenous iron replacement therapy drug developed
by Switzerland’s Vifor (International) AG and to date, it has been approved as an indication for thetreatment of iron deficiency anemia and iron deficiency in 83 countries worldwide.
Phase III clinical trials conducted in Japan involved patients being administered 500mg of this treatment
once a week for a period of two to three weeks, and the results verified non-inferiority to saccharated
iron oxide, the reference drug. There was also no difference in terms of safety (occurrences of adverse
events or effects) that might present a problem.
We expect this treatment to contribute to healthcare as a new option for treating iron deficiency anemia.

Tillotts Pharma succeeded to the rights to manufacture and sell DIFICLIR from Astellas Pharma Europe Ltd.
In November 2020, our wholly owned subsidiary Tillotts Pharma AG of Switzerland succeeded to therights to manufacture and sell DIFICLIR (product name: DIFICLIR, generic name: Fidaxomicin), a
treatment for Clostridium difficile* 1 infections, in Europe, the Middle East, Africa, and theCommonwealth of Independent States (CIS)*2 from Astellas Pharma Europe Ltd., the UK subsidiary of
Astellas Pharma Inc.
The addition of DIFICLIR into the Tillotts Pharma product lineup is expected to create synergistic effects
with its existing portfolio and raise the presence of the company within Europe.
*1 Clostridium difficile (C. difficile): A bacteria that resides in small quantities within the large intestine. A proper balance ofintestinal bacteria prevents C. difficile from proliferating. However, the ingestion of antibacterial agents with a large
antimicrobial spectrum can destroy the balance of intestinal bacteria and cause C. difficile to proliferate in unusual numbers.
The toxins produced by this can result in colitis, severe diarrhea, and in worst case scenarios, death.
*2 Commonwealth of Independent States (CIS): A free coalition composed primarily of sovereign nations that were once part of
the Soviet Union.

9

Obtained approval to manufacture and market Belfemin® (pharmaceutical requiring guidance),
a treatment for ameliorating foot swelling caused by mild venous insufficiency
On November 30, 2020, we received approval from the Ministry of Health, Labour and Welfare to
manufacture and market Belfemin, a treatment for ameliorating foot swelling caused by mild venous
insufficiency (disruption to the flow of blood through veins).
Belfemin is a pharmaceutical containing the extract of dried European horse-chestnut (Aesculus
hippocastanum L.) seeds as an active ingredient. European horse-chestnut is traditionally used in Europe
to treat lower-limb venous disorders (chronic venous insufficiency). This treatment first went on sale inGermany in 1968 and it has been sold as a non-prescription drug for ameliorating various lower-limb
venous disorders (chronic venous insufficiency) in dozens of countries, including Switzerland and Norway.
In September 2014, Zeria launched Prefemin, a direct OTC drug based on European herbal medicine
that is effective for ameliorating PMS. In addition to Belfemin, our second direct OTC drug based on
European herbal medicine, we will further enhance our lineup of European herbal medicine products.

10

Financial Statements (Consolidated)

Consolidated Balance Sheets (Summary)
Term
Item

(Unit: ¥million*)

Previous Fiscal Year Current Fiscal Year(As of March 31, 2020) (As of March 31, 2021)

Item

Previous Fiscal Year Current Fiscal Year(As of March 31, 2020) (As of March 31, 2021)

Liabilities

Assets41,07053,757

Accounts Payable - Trade

1,587

1,693

Short-Term Borrowings

29,705

44,158

Other

9,777

7,904

Non-current Liabilities

10,406

11,922

2,918

Long-Term Borrowings

5,470

5,819

(130)

(138)

Retirement Benefit Liability

1,123

1,308

69,13584,546

Asset Retirement Obligations

55

55

Property, Plant and Equipment

23,12523,634

3,757

4,738

51,47765,679Buildings and Structures

7,073

7,373

Machinery, Equipment and Vehicles

2,700

2,239

49,264

49,661

Land

11,66012,350Share Capital

6,593

6,593

75

116

Capital Surplus

11,685

11,685

Other

1,616

1,553

Retained Earnings

44,832

46,380Intangible Assets

29,84842,069Treasury Shares(13,846)(14,997)

Investments and Other Assets

16,162

18,842

3,246

6,350

Investment Securities

5,968

5,915

Valuation Difference on
Available-for-Sale Securities

(457)

137

Deferred Tax Assets

85

67

Foreign Currency
Translation Adjustment

1,648

2,599

9,759

12,453Remeasurements ofDefined Benefit Plans

2,054

3,614

Other

354

443

Non-Controlling Interests

168

167

Allowance for Doubtful Accounts

(6)

(37)

Total Net Assets

52,67856,179104,155

121,859

Total Liabilities and Net Assets

104,155

121,859

35,02037,313

Cash and Deposits

9,005

9,793

Notes and Accounts Receivable-Trade

13,36913,635Inventories

9,563

11,104

Other

3,212

Allowance for Doubtful Accounts

Current Assets

Non-current Assets

Construction in Progress

Retirement Benefit Asset

Total Assets

11

Term

Current Liabilities

Other
Total Liabilities
Net Assets
Shareholders’ Equity

Accumulated Other
Comprehensive Income

Unit: ¥million rounded down to nearest million

Consolidated Statements of Income (Summary)
Term
Item

(Unit: ¥million*)

Consolidated Statements of Cash Flows (Summary)Previous Fiscal Year Current Fiscal Year
(From April 1, 2019
to March 31, 2020)(From April 1, 2020
to March 31, 2021)

60,426
16,643
43,78346
38
43,791
39,696
4,094
310
525
3,879
44
3
3,920
527
453
2,938
13
2,925

55,442
15,796
39,64538
48
39,63436,192
3,442
373
640
3,175
1,058
310
3,922
837
(45)
3,131
11
3,119

Net Sales
Cost of Sales
Gross Profit
Reversal of Provision for Sales Returns
Provision for Sales Returns
Gross Profit - Net
Selling, General and Administrative Expenses
Operating Profit
Non-Operating Income
Non-Operating Expenses
Ordinary Profit
Extraordinary Income
Extraordinary Losses
Profit before Income Taxes
Income Taxes - Current
Income Taxes - Deferred
ProfitProfit Attributable to Non-Controlling Interests
Profit Attributable to Owners of Parent

Term
Item

(Unit: ¥million*)

Previous Fiscal Year Current Fiscal Year
(From April 1, 2019
to March 31, 2020)(From April 1, 2020
to March 31, 2021)

Net Cash Provided by (Used in)Operating Activities

7,251

6,894

Net Cash Provided by (Used in)Investing Activities(405)(17,460)

Net Cash Provided by (Used in)
Financing Activities(5,877)

11,185

Effect of Exchange Rate Change
on Cash and Cash Equivalents

(52)

169

Net Increase (Decrease) in
Cash and Cash Equivalents

916

788

Cash and Cash Equivalents
at Beginning of Period

7,920

8,880

Increase (Decrease) in Cash andCash Equivalents Resulting from
Change in Scope of Consolidation

43-

Cash and Cash Equivalents
at End of Period

8,880

9,668

Unit: ¥million rounded down to nearest million

Unit: ¥million rounded down to nearest million

Consolidated Statements of Changes in Equity (Summary) (From April 1, 2020 to March 31, 2021)
Shareholders’ Equity
Share
CapitalBalance at Beginning of Period

6,593

CapitalSurplusRetained
Earnings

Treasury
Shares

11,68544,832(13,846)(Unit: ¥million*)

Accumulated Other Comprehensive Income
NonValuation
Foreign
Total Accumulated
Total
Controllingon
Currency Remeasurements
Other
Shareholders’ DifferenceofDefinedInterests
Available-for- Translation
Comprehensive
EquitySale Securities Adjustment Benefit Plans
Income49,264

(457)

1,648

2,054

3,246

168

Total Net
Assets52,678Changes during Period
Dividends of Surplus(1,571)(1,571)

Profit Attributable to Owners of Parent

3,119

3,119

3,119

(1,151)(1,151)(1,151)

Purchase of Treasury Shares
Net Changes in Items Other
than Shareholders’ Equity
Total Changes during Period
Balance at End of Period(1,571)

594

950

1,559

3,104

(0)

-

-

1,548

(1,151)

397

594

950

1,559

3,104

(0)

3,103
3,501

6,593

11,68546,380(14,997)

49,661

137

2,599

3,614

6,350

167

56,179

Unit: ¥million rounded down to nearest million

12Company Information (As of March 31, 2021)

Company Outline

Place of Business

Established:

December 1955

● Headquarters● Central Research Laboratories

Share Capital:¥6,593,398,500● Sapporo Branch● Saitama Plant

Number of Employees:

1,690 (Consolidated)● Sendai Branch● Tsukuba Plant

Business Activities:

1.‌Manufacturing, sales, import andexport of pharmaceuticals,quasi-drugs and reagents.
2.‌Manufacturing, sales, import andexport of cosmetics, health foods,
soft drinks, hygienic goods andmedical devices.

● Tokyo Branch● Sapporo Distribution Center● Nagoya Branch● Tokyo Distribution Center● Osaka Branch● Saitama Distribution Center● Chugoku & Shikoku Branch● Osaka Distribution Center● Fukuoka Branch● Kyushu Distribution Center

Directors and Audit & Supervisory Board Members(As of June 29, 2021)

Chairman and CEO

Sachiaki Ibe

President and COO

Mitsuhiro Ibe

Executive Vice President

Hirokazu EndoManaging Director

Makoto Kishimoto

Director

Tetsuo Komori

Director

Kikuo Nomoto

Director

Seiji Morimoto

Director

Hiroki Kato

Director

Yoshihiro Hiraga● Tillotts Pharma Spain S.L.U. (Spain)

Director

Toshiaki Kawagoe● Tillotts Pharma GmbH (Germany)

Director

Kenji Kusano

Director

Yuuki Okazawa

Audit & Supervisory Board Member Koujirou Takami
Audit & Supervisory Board Member Keiji Ishiyama
Audit & Supervisory Board Member (Outside) Yukiko Naka
Audit & Supervisory Board Member (Outside) Masaru Kamisuki

13

Main Subsidiaries (As of June 29, 2021)● Tillotts Pharma AG (Switzerland)● Tillotts Pharma AB (Sweden)● Tillotts Pharma Ltd. (Ireland)● Tillotts Pharma UK Ltd. (United Kingdom)● Tillotts Pharma Czech s.r.o. (Czech Republic)● Tillotts Pharma France SAS (France)● Tillotts Pharma Italy s.r.l. (Italy)● Pharmaceutical Joint Stock Company of February 3rd (Vietnam)● ZPD A/S (Denmark)● Zeria Healthway Co., Ltd.
● IONA INTERNATIONAL CORPORATION● Kenso-Seiyaku Co., Ltd.
● Zevice Co., Ltd.

Share Information (As of March 31, 2021)

Status of Shares

Distribution of Shares by Shareholder Type(i) Number of authorized shares:

119,860,000 shares(ii) Number of shares outstanding:

53,119,190 shares(iii) Number of shareholders:

Financial Instruments
Business

10,721

3,122,884 shares(5.88%)

436,285 shares(0.82%)

Major Shareholders
Number of
Shares Held

Percentage
Held (%)

Ibe Corporation

4,741,847

10.4

The Master Trust Bank of Japan, Ltd.
(Trust Account)

2,115,400

4.6

MUFG Bank, Ltd.

2,107,050

4.6

Morinaga Milk Industry Co., Ltd.

1,840,215

4.0

Sachiaki Ibe

1,592,967

3.5

Sumitomo Mitsui Banking Corporation

1,406,131

3.1

Mizuho Bank, Ltd.

1,406,053

3.1

Resona Bank, Limited

Name of Shareholder

Foreigners

1,182,385

2.6

Aioi Nissay Dowa Insurance Co., Ltd.

944,560

2.1

SMBC Finance Service Co., Ltd.

900,900

2.0

Individual Shareholders
and Others
17,580,221 shares(33.09%)Distribution
Ratio of Shares
Total
53,119,190 shares
Other Domestic
Corporations
16,263,071 shares(30.62%)Financial Institutions
15,716,729 shares(29.59%)(Note) The percentage held is calculated by subtracting treasury shares (totaling 7,420,461 shares).

Share Price and Trading Volume
Share Price (¥)

2,500
2,000

Number of
Shares Traded(1,000 shares)

1,500

3,000
2,500

1,000

2,000
1,500

500

1,000
500

0

2020
April

May

June

July

AugustSeptember

OctoberNovember December

2021
January0
February

March

14

Shareholder Memo
Fiscal Year
From April 1st of each year to March 31st of the following year
Ordinary General Meeting of Shareholders
Late June of each year
Record Date
Ordinary General Meeting of Shareholders and end of term dividend:
March 31 of each year
Interim dividend: September 30 of each year
Transfer Agent
Sumitomo Mitsui Trust Bank, Limited
1-4-1 Marunouchi, Chiyoda-ku, Tokyo
Account Management Institution for Special Account
Sumitomo Mitsui Trust Bank, Limited
1-4-1 Marunouchi, Chiyoda-ku, Tokyo

Mailing Address (Inquiry information)
Stock Transfer Agency Business Planning Department,
Sumitomo Mitsui Trust Bank, Limited
2-8-4 Izumi, Suginami-ku, Tokyo 168-0063
TEL: 0120-782-031 (toll-free)Handling operation is conducted in main branch and all
domestic branches of Sumitomo Mitsui Trust Bank, Limited.
● Applications for change of address or for purchase demandsof fractional shares, etc.
Please send such notifications or applications to the securities
company where your account is held.
For shareholders for whom a special account has been opened
because there is no account held by a securities company,
please send such notifications or applications to Sumitomo
Mitsui Trust Bank, Limited, the account management
institution for the special account.
● Applications for payment of dividends payable
Please send such applications to the transfer agent, Sumitomo
Mitsui Trust Bank, Limited.

Please refer to latest IR information on our website.
The Company has set up a website for the purpose of providing accurate information
on a timely basis. The website contains a broad array of information useful forshareholders and investors, from IR information to the latest news.

https://www.zeria.co.jp/english/

Customer Service, Zeria Pharmaceutical Co., Ltd.
10-11 Nihonbashi-kobunacho, Chuo-ku, Tokyo 103-8351
TEL 03-3663-2351 (Main) FAX 03-3663-2352
03-3661-2080
https://www.zeria.co.jp/